BCR/ABL1-positive B-lymphoblastic Lymphoma Successfully Treated with Dasatinib-combined Chemotherapy

Intern Med. 2021 Oct 1;60(19):3149-3153. doi: 10.2169/internalmedicine.7066-21. Epub 2021 Apr 5.

Abstract

We herein report a rare case of BCR-ABL1-positive B-lymphoblastic lymphoma (B-LBL). An 18-year-old woman had a history of persistent left-sided chest pain. Positron emission tomography showed increased metabolic activity in the fifth rib, duodenum, and pancreas. The pathological findings of the pancreas, duodenum, and bone marrow confirmed the diagnosis of B-LBL. Polymerase chain reaction of duodenum and bone marrow also revealed a minor BCR-ABL1 fusion gene. She was diagnosed with BCR-ABL1-positive B-LBL and administered dasatinib and prednisolone. She achieved complete remission two weeks after the initiation of the treatment. She received stem cell transplantation after consolidation chemotherapy and sustained complete remission.

Keywords: B-lymphoblastic lymphoma; BCR-ABL1; dasatinib; tyrosine kinase inhibitors.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Dasatinib / therapeutic use
  • Female
  • Fusion Proteins, bcr-abl* / genetics
  • Humans
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma*
  • Protein Kinase Inhibitors
  • Tomography, X-Ray Computed

Substances

  • Protein Kinase Inhibitors
  • Fusion Proteins, bcr-abl
  • Dasatinib